Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenu archivé le 2024-06-18

Targeting microRNAs for ColoRectal Cancer Therapy

Objectif

MicroRNAs are small non-coding RNAs involved in cell homeostasis and carcinogenesis. MicroRNA deregulation is associated with colorectal cancer (CRC) progression. My study proposes to identify genetic and epigenetic events leading to microRNAs deregulation and use them as targets for drug development. My research proposal will address two important questions. First it will assess the contribution of genetic and epigenetic events in controlling microRNA genes and cancer phenotype. Second it will define synthetic lethal interaction between microRNA genes aberration and kinase genes in order to define novel target for therapy.
Mutations and promoter methylation of microRNA genes and microRNA processing genes will be analyzed by massive parallel sequencing in a first cohort of CRC. Mathematical and in vitro analysis will be performed to test whether a mutation is a driver or passenger one. The frequency of driver mutations and promoter methylation will be confirmed in a large case-control study encompassing 2500 CRC patients. Mutational and methylation status will be matched with clinical-pathological features in order to detect correlations with clinical outcome. In order to translate my findings into drug development, genetic aberration in microRNA genes will be reproduced in CRC cell lines. Isogenic cell lines harboring the wild type or the mutant allele will be tested for cell viability in a parallel RNAi screening using siRNA libraries targeting kinase. Protein kinases are important mediators of microRNA function. More importantly, catalytic inhibitors of kinase can be easily developed making them attractive targets for synthetic lethality screening and drug development.

Appel à propositions

FP7-PEOPLE-2012-CIG
Voir d’autres projets de cet appel

Coordinateur

INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG
Contribution de l’UE
€ 9 341,39
Adresse
OLD BROMPTON ROAD 123
SW7 3RP London
Royaume-Uni

Voir sur la carte

Région
London Inner London — West Kensington & Chelsea and Hammersmith & Fulham
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Angus Bell (Dr.)
Liens
Coût total
Aucune donnée

Participants (1)